For ER-positive HER2-negative BC, the combination of ribociclib, fulvestrant, and a PI3K inhibitor (BKM120 or BYL719) has been investigated (NCT02088684) and those results are eagerly awaited to investigate first the MTD and then the efficacies of these combinations. Here, PIK3CA is linked to breast cancer.